Hodgkin's lymphoma: current treatment strategies and novel approaches.
about
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.RECRUIT-TandAbs: harnessing the immune system to kill cancer cells.Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma.
P2860
Hodgkin's lymphoma: current treatment strategies and novel approaches.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hodgkin's lymphoma: current treatment strategies and novel approaches.
@en
Hodgkin's lymphoma: current treatment strategies and novel approaches.
@nl
type
label
Hodgkin's lymphoma: current treatment strategies and novel approaches.
@en
Hodgkin's lymphoma: current treatment strategies and novel approaches.
@nl
prefLabel
Hodgkin's lymphoma: current treatment strategies and novel approaches.
@en
Hodgkin's lymphoma: current treatment strategies and novel approaches.
@nl
P2093
P2860
P356
P1476
Hodgkin's lymphoma: current treatment strategies and novel approaches.
@en
P2093
Andreas Engert
Dennis A Eichenauer
German Hodgkin Study Group
Michael Fuchs
Peter Borchmann
P2860
P356
10.1586/17474086.1.1.63
P577
2008-10-01T00:00:00Z